TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the U.S. commercial launch of Consensi™, a fixed-dose combination of celecoxib and amlodipine besylate, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov’s U.S. distributor, Coeptis Pharmaceuticals.
“Consensi™ provides a new therapeutic option for patients suffering from both hypertension and osteoarthritis-related pain. We are excited about the availability of Consensi™ for patients”, said Dave Mehalick, Chief Executive Officer of Coeptis Pharmaceuticals.
“We are please Consensi™ is now available and our sales team is eager to introduce this one tablet, once a day treatment for hypertension and osteoarthritis pain to the U.S. market”, said Angela Sutterer, Chief Executive Officer of Burke Therapeutics.
“The initial U.S. sales of Consensi™ represents a key milestone for Kitov,” said Isaac Israel, Chief Executive Officer of Kitov. “We are confident that Coeptis’ and Burke’s extensive distribution reach will enable us to maximize Consensi™’s market potential. The projected royalties and milestone revenues from our U.S. marketing and distribution agreements for Consensi™, together with the $26 million gross fundraising proceeds we secured this year, will provide the source of financial support for our development efforts aimed at advancing our emerging oncology pipeline, including advancing both NT-219 and CM-24 into significant value creating clinical milestones. We look forward to providing further updates about Consensi™’s marketing activities and progress soon.”
About Kitov Pharma
Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov’s oncology pipeline includes NT-219 and CM-24. NT-219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. Kitov is currently advancing NT-219 in combination with cetuximab as a third-line or second-line treatment option for the treatment of recurrent and metastatic squamous cell carcinoma of head & neck cancer (SCCHN), as well as a single agent monotherapy treatment in patients with advanced solid tumors in a planned phase 1/2 study. CM-24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. Kitov plans to advance CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer NSCLC and pancreatic cancer. Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb Company for the planned phase 1/2 clinical trials to evaluate the combination of CM-24 with the PD-1 inhibitor nivolumab (Opdivo®). Kitov is also the owner of Consensi™, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension which was approved by the FDA for marketing in the U.S in May 2018 and was launched in the U.S. in May 2020 by its partner Coeptis Pharmaceuticals in the U.S.. Kitov has also partnered to commercialize Consensi in China and South Korea. The company is headquartered in Tel Aviv, Israel. For more information, please visit http://www.kitovpharma.com.
Consensi is a fixed-dose combination of amlodipine besylate, a calcium channel blocker for the treatment of hypertension, to lower blood pressure, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) for the management of the signs and symptoms of osteoarthritis. The U.S. Food & Drug Administration (FDA) approved Consensi oral tablets for marketing in the U.S..